- €3.57m
- €2.53m
- €12.54m
- 37
- 30
- 53
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.88 | ||
| Price to Tang. Book | 1.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -11.63% | ||
| Return on Equity | -1.3% | ||
| Operating Margin | -2.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 8.28 | 8.98 | 11.32 | 13.17 | 12.54 | n/a | n/a | 12.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -75.08 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Integragen SA is a France-based company active in the healthcare sector. It researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. It uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). It also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The Company also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
Directors
- Jean Stephenne CHM
- Bernard Courtieu CEO
- Pierre Flamant FID
- Emmanuel Martin COO
- Catherine David MGB
- Berengere Genin MGB
- Larry Yost MGB
- Alain Declercq DRC
- Jean-pol Detiffe DRC
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 26th, 2000
- Public Since
- June 18th, 2010
- No. of Employees
- 44
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Euronext - Paris- Shares in Issue
- 6,613,144
- Address
- Genopole Campus 1, EVRY, 91000
- Web
- https://integragen.com/
- Phone
- +33 160910900
- Contact
- Louis-victor Delouvrier
- Auditors
- Deloitte & Associes
Upcoming Events for ALINT
Similar to ALINT
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Cellectis SA
Euronext - Paris
FAQ
What is the IntegraGen SA share price?
As of Today at 21:20 UTC, shares in IntegraGen SA are trading at €0.54. This share price information is delayed by 15 minutes.
How has the IntegraGen SA share price performed this year?
Shares in IntegraGen SA last closed at €0.54 and the price had moved by -10% over the past 365 days. In terms of relative price strength the IntegraGen SA share price has underperformed the FTSE Global All Cap Index by -12.25% over the past year.
What are the analyst and broker recommendations for IntegraGen SA?
The overall consensus recommendation for IntegraGen SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the IntegraGen SA dividend yield?
IntegraGen SA does not currently pay a dividend.
Does IntegraGen SA pay a dividend?
IntegraGen SA does not currently pay a dividend.
When does IntegraGen SA next pay dividends?
IntegraGen SA does not currently pay a dividend.
How do I buy IntegraGen SA shares?
To buy shares in IntegraGen SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IntegraGen SA?
As of the previous close price of €0.54, shares in IntegraGen SA had a market capitalisation of €3.57m.
Where are IntegraGen SA shares listed?
Here are the trading details for IntegraGen SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALINT
What kind of share is IntegraGen SA?
Based on an overall assessment of its quality, value and momentum IntegraGen SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IntegraGen SA share price forecast for 2025?
The analyst consensus target price for shares in IntegraGen SA is €2.35. That is 335.19% above the last closing price of €0.54.
Analysts covering IntegraGen SA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the IntegraGen SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IntegraGen SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +3.71%.
As of the last closing price of €0.54, shares in IntegraGen SA were trading -1.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IntegraGen SA PE Ratio?
The IntegraGen SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IntegraGen SA?
IntegraGen SA's management team is headed by:
- Jean Stephenne - CHM
- Bernard Courtieu - CEO
- Pierre Flamant - FID
- Emmanuel Martin - COO
- Catherine David - MGB
- Berengere Genin - MGB
- Larry Yost - MGB
- Alain Declercq - DRC
- Jean-pol Detiffe - DRC